115 related articles for article (PubMed ID: 16612282)
1. Suppression of the cell-mediated immune response by a Fas-immunoglobulin fusion protein.
Shen Y; Young B; Lipman ML
Transplantation; 2006 Apr; 81(7):1041-8. PubMed ID: 16612282
[TBL] [Abstract][Full Text] [Related]
2. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
Bonardelle D; Benihoud K; Kiger N; Bobé P
J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
[TBL] [Abstract][Full Text] [Related]
3. B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo.
Kosiewicz MM; Krishnan A; Worthington MT; Matriano JA; Ross WG
Eur J Immunol; 2002 Jun; 32(6):1679-87. PubMed ID: 12115651
[TBL] [Abstract][Full Text] [Related]
4. In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor.
Connolly K; Cho YH; Duan R; Fikes J; Gregorio T; LaFleur DW; Okoye Z; Salcedo TW; Santiago G; Ullrich S; Wei P; Windle K; Wong E; Yao XT; Zhang YQ; Zheng G; Moore PA
J Pharmacol Exp Ther; 2001 Jul; 298(1):25-33. PubMed ID: 11408521
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
Georgantas RW; Bohana-Kashtan O; Civin CI
Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
[TBL] [Abstract][Full Text] [Related]
6. Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells.
Mohamood AS; Trujillo CJ; Zheng D; Jie C; Murillo FM; Schneck JP; Hamad AR
Int Immunol; 2006 Aug; 18(8):1265-77. PubMed ID: 16769751
[TBL] [Abstract][Full Text] [Related]
7. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of dichotomous action of IL-2-Pseudomonas exotoxin 40 (IL-2-PE40) on cell-mediated and humoral immune response.
Volk HD; Müller S; Yarkoni S; Diamantstein T; Lorberboum-Galski H
J Immunol; 1994 Sep; 153(6):2497-505. PubMed ID: 8077661
[TBL] [Abstract][Full Text] [Related]
9. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
10. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.
Kunzendorf U; Pohl T; Bulfone-Paus S; Krause H; Notter M; Onu A; Walz G; Diamantstein T
J Clin Invest; 1996 Mar; 97(5):1204-10. PubMed ID: 8636431
[TBL] [Abstract][Full Text] [Related]
11. An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression.
Bulfone-Paus S; Rückert R; Krause H; von Bernuth H; Notter M; Pohl T; Tran TH; Paus R; Kunzendorf U
Transplantation; 2000 Apr; 69(7):1386-91. PubMed ID: 10798759
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions.
Taylor L; Bachler M; Duncan I; Keen S; Fallon R; Mair C; McDonald TT; Schwarz H
J Leukoc Biol; 2002 Sep; 72(3):522-9. PubMed ID: 12223520
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4.FasL inhibits allogeneic responses in vivo.
Dranitzki-Elhalel M; Huang JH; Rachmilewitz J; Pappo O; Parnas M; Schmidt W; Tykocinski ML
Cell Immunol; 2006 Feb; 239(2):129-35. PubMed ID: 16828466
[TBL] [Abstract][Full Text] [Related]
15. Overexpressed exogenous IL-4 And IL-10 paradoxically regulate allogenic T-cell and cardiac myocytes apoptosis through FAS/FASL pathway.
Furukawa H; Oshima K; Tung T; Cui G; Laks H; Sen L
Transplantation; 2008 Feb; 85(3):437-46. PubMed ID: 18301335
[TBL] [Abstract][Full Text] [Related]
16. CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.
Dranitzki-Elhalel M; Huang JH; Sasson M; Rachmilewitz J; Parnas M; Tykocinski ML
Int Immunol; 2007 Apr; 19(4):355-63. PubMed ID: 17314083
[TBL] [Abstract][Full Text] [Related]
17. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
18. [The expression and application of human Fas ligand in E.coli].
Li NL; Nie H; Yu QW; Bo J; Ma AL; Zhang JY; Shen BH; Wang L; Zhang DQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):20-2. PubMed ID: 15132896
[TBL] [Abstract][Full Text] [Related]
19. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
[TBL] [Abstract][Full Text] [Related]
20. Distinct overexpression of Fas ligand on T lymphocytes in aplastic anemia.
Li W; Fu J; Wang F; Yu G; Wang Y; Zhang X
Cell Mol Immunol; 2004 Apr; 1(2):142-7. PubMed ID: 16212902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
